| scholarly article | Q13442814 |
| P50 | author | John Ioannidis | Q6251482 |
| Deborah Ashby | Q20876093 | ||
| Paolo Vineis | Q25999450 | ||
| Carlotta Sacerdote | Q30831084 | ||
| Karin van Veldhoven | Q60008170 | ||
| Ioanna Tzoulaki | Q63378793 | ||
| P2093 | author name string | Naomi E Allen | |
| Konstantinos K Tsilidis | |||
| Evangelos C Rizos | |||
| David S Lopez | |||
| Despoina Capothanassi | |||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | metformin | Q19484 |
| P304 | page(s) | 2522-2532 | |
| P577 | publication date | 2014-06-04 | |
| P1433 | published in | Diabetes Care | Q5270111 |
| P1476 | title | Metformin does not affect cancer risk: a cohort study in the U.K. Clinical Practice Research Datalink analyzed like an intention-to-treat trial | |
| P478 | volume | 37 |
| Q53282862 | A Cohort Study of Metformin and Colorectal Cancer Risk among Patients with Diabetes Mellitus. |
| Q39124486 | A spatiotemporal hypothesis for the regulation, role, and targeting of AMPK in prostate cancer. |
| Q37232678 | Alpha-glucosidase inhibitors and hepatotoxicity in type 2 diabetes: a systematic review and meta-analysis |
| Q47440388 | An update of research evidence on nutrition and prostate cancer |
| Q61800715 | Association Between Metformin and Sulfonylurea Monotherapies and Cancer Incidence: A Real-World Cohort Study in Shanghai, China |
| Q36145731 | Association between Metformin Therapy and Breast Cancer Incidence and Mortality: Evidence from a Meta-Analysis |
| Q36133307 | Association of diabetes and cancer mortality in American Indians: the Strong Heart Study |
| Q36568614 | Association of diabetes and diabetes treatment with incidence of breast cancer |
| Q90470049 | Association of metformin intake with bladder cancer risk and oncologic outcomes in type 2 diabetes mellitus patients: A systematic review and meta-analysis |
| Q28545791 | Basal Autophagy and Feedback Activation of Akt Are Associated with Resistance to Metformin-Induced Inhibition of Hepatic Tumor Cell Growth |
| Q38652183 | Cancer Prevention: Lessons Learned and Future Directions |
| Q36024628 | Cancer risk in patients aged 30 years and above with type 2 diabetes receiving antidiabetic monotherapy: a cohort study using metformin as the comparator |
| Q38858585 | Cancer risk of sulfonylureas in patients with type 2 diabetes mellitus: A systematic review |
| Q30242051 | Cancer, obesity, diabetes, and antidiabetic drugs: is the fog clearing? |
| Q38976502 | Comparative Effect of Initiating Metformin Versus Sulfonylureas on Breast Cancer Risk in Older Women |
| Q37228939 | Comparative safety of diabetes medications and risk of incident invasive breast cancer: a population-based cohort study |
| Q48146168 | Diabetes Mellitus and Risk of Hepatocellular Carcinoma. |
| Q26741205 | Diabetes mellitus and metformin in hepatocellular carcinoma |
| Q36716002 | Diabetes, Diabetes Treatment, and Risk of Thyroid Cancer |
| Q28081491 | Dissecting the Dual Role of AMPK in Cancer: From Experimental to Human Studies |
| Q38687543 | Does Metformin Reduce Cancer Risks? Methodologic Considerations |
| Q28542653 | Dose-Dependent AMPK-Dependent and Independent Mechanisms of Berberine and Metformin Inhibition of mTORC1, ERK, DNA Synthesis and Proliferation in Pancreatic Cancer Cells |
| Q60303330 | Dual Inhibition of the Lactate Transporters MCT1 and MCT4 Is Synthetic Lethal with Metformin due to NAD+ Depletion in Cancer Cells |
| Q38558943 | Expanding the therapeutic spectrum of metformin: from diabetes to cancer. |
| Q33672932 | Meta-analysis of studies using metformin as a reducer for liver cancer risk in diabetic patients |
| Q26765139 | Metformin Is Associated With Slightly Reduced Risk of Colorectal Cancer and Moderate Survival Benefits in Diabetes Mellitus: A Meta-Analysis |
| Q64226496 | Metformin Use and Lung Cancer Risk in Diabetic Patients: A Systematic Review and Meta-Analysis |
| Q38999875 | Metformin and cancer in type 2 diabetes: a systematic review and comprehensive bias evaluation |
| Q39944738 | Metformin for chemoprevention of metachronous colorectal adenoma or polyps in post-polypectomy patients without diabetes: a multicentre double-blind, placebo-controlled, randomised phase 3 trial. |
| Q91925534 | Metformin in colorectal cancer: molecular mechanism, preclinical and clinical aspects |
| Q38996447 | Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial |
| Q49712304 | Metformin reduces the risk of cancer in patients with type 2 diabetes: An analysis based on the Korean National Diabetes Program Cohort |
| Q92131580 | Metformin reverses mesenchymal phenotype of primary breast cancer cells through STAT3/NF-κB pathways |
| Q28069605 | Metformin therapy and risk of colorectal adenomas and colorectal cancer in type 2 diabetes mellitus patients: A systematic review and meta-analysis |
| Q46255692 | Metformin transiently inhibits colorectal cancer cell proliferation as a result of either AMPK activation or increased ROS production. |
| Q90324219 | Metformin use and incidence cancer risk: evidence for a selective protective effect against liver cancer |
| Q92524384 | Metformin use and prostate cancer risk: A meta-analysis of cohort studies |
| Q64230539 | Metformin use and risk of cancer in patients with type 2 diabetes: a cohort study of primary care records using inverse probability weighting of marginal structural models |
| Q36356897 | Metformin use and the risk of colorectal adenoma: A systematic review and meta-analysis |
| Q48268841 | Metformin, Asian ethnicity and risk of prostate cancer in type 2 diabetes: a systematic review and meta-analysis |
| Q92451061 | Metformin-repressed miR-381-YAP-snail axis activity disrupts NSCLC growth and metastasis |
| Q38584636 | Metformin: risk-benefit profile with a focus on cancer |
| Q91900872 | Monotherapy with Metformin versus Sulfonylureas and Risk of Cancer in Type 2 Diabetic Patients: A Systematic Review and Meta-Analysis |
| Q89989620 | New drugs are not enough‑drug repositioning in oncology: An update |
| Q40778391 | No reduced risk of overall, colorectal, lung, breast, and prostate cancer with metformin therapy in diabetic patients: database analyses from Germany and the UK. |
| Q28084566 | Nutrition, dietary interventions and prostate cancer: the latest evidence |
| Q26786829 | Obesity and cancer: mechanistic insights from transdisciplinary studies |
| Q38884916 | Pancreatic cancer actionable genes in precision medicine and personalized surgery |
| Q59138314 | Pleiotropic Effects of Metformin on Cancer |
| Q34149590 | Poor glycemic control of diabetes mellitus is associated with higher risk of prostate cancer detection in a biopsy population |
| Q39030844 | Potential and real 'antineoplastic' and metabolic effect of metformin in diabetic and nondiabetic postmenopausal females |
| Q36225691 | Preventing Allograft Rejection by Targeting Immune Metabolism |
| Q64433311 | Prevention of Colorectal Neoplasia |
| Q37561605 | Prospective study of Type 2 diabetes mellitus, anti-diabetic drugs and risk of prostate cancer |
| Q92410918 | Prostate Cancer Energetics and Biosynthesis |
| Q38993013 | Prostate Cancer Patients With Unmanaged Diabetes or Receiving Insulin Experience Inferior Outcomes and Toxicities After Treatment With Radiation Therapy |
| Q43834371 | Re.: "Reduced risk of lung cancer with metformin therapy in diabetic patients: a systematic review and meta-analysis". |
| Q41083568 | Recent advances in the use of metformin: can treating diabetes prevent breast cancer? |
| Q39782952 | Reduced colorectal cancer incidence in type 2 diabetic patients treated with metformin: a meta-analysis |
| Q92507283 | Relationship between Diabetes and Diabetes Medications and Risk of Different Molecular Subtypes of Breast Cancer |
| Q40075959 | Risk Model for Prostate Cancer Using Environmental and Genetic Factors in the Spanish Multi-Case-Control (MCC) Study |
| Q48252582 | Survival benefit associated with metformin use in inoperable non-small cell lung cancer patients with diabetes: A population-based retrospective cohort study |
| Q34548130 | Syrosingopine sensitizes cancer cells to killing by metformin |
| Q38728567 | The expanding role of metformin in cancer: an update on antitumor mechanisms and clinical development |
| Q35118801 | The metabolic state of cancer stem cells-a valid target for cancer therapy? |
| Q40900704 | The phenomenon of acquired resistance to metformin in breast cancer cells: The interaction of growth pathways and estrogen receptor signaling. |
| Q33756414 | Type 2 Diabetes Mellitus and Cancer: The Role of Pharmacotherapy |
| Q41050215 | Type 2 diabetes mellitus and risk of hepatocellular carcinoma: spotlight on nonalcoholic fatty liver disease. |
| Q94539110 | Type 2 diabetes, breast cancer specific and overall mortality: Associations by metformin use and modification by race, body mass, and estrogen receptor status |
Search more.